Capforce Inc. (CFOR) Stock Price & Analysis
Capforce Inc. (CFOR) fell 10.00% to USD 18 as of July 25, 2026 at 03:57 UTC, according to Nexqual real-time market data.
CFOR last closed at USD 20; the session ranged USD 9.51–19.5 on volume of 1,920 shares. Market capitalization is $222.91M, with a 52-week range of USD 0–34 (OID). Source: Nexqual, July 25, 2026 at 03:57 UTC.
Key Statistics (as of July 25, 2026 at 03:57 UTC)
| Price | USD 18 |
|---|---|
| Change | ▼ 10.00% (down) |
| Previous Close | USD 20 |
| Open | USD 11 |
| Day Range | USD 9.51 – 19.5 |
| 52-Week Range | USD 0 – 34 |
| Volume | 1,920 shares |
| Market Cap | $222.91M |
| Exchange | OID |
Technical Analysis (CFOR)
Nexqual's technical model rates CFOR "STRONG BUY" based on 5 bullish and 0 bearish signals across 125 daily candles, as of July 25, 2026 at 03:57 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 57.88 (neutral) |
| vs SMA50 | Above (USD 7.57) |
| MACD | 2.74 (positive) |
Analyst Ratings (CFOR)
Wall Street analysts rate CFOR "None", per Nexqual as of July 25, 2026 at 03:57 UTC.
| Consensus Rating | None |
|---|
Earnings (CFOR)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-09-30 | USD -4.6 vs est -4.3 ▼ miss |
| 2023-06-30 | USD -9.3 vs est -7.1 ▼ miss |
| 2022-12-31 | USD -18.97 vs est -20 ▲ beat |
Source: Nexqual, July 25, 2026 at 03:57 UTC.
Financials & Fundamentals (CFOR)
| Total Revenue | $30.20M |
|---|---|
| Gross Margin | +90.00% |
| Operating Margin | +78.63% |
| Profit Margin | +77.21% |
| ROE | +121.73% |
| Debt / Equity | 5.76 |
| Current Ratio | 0.1 |
| Total Cash | $78,586 |
| Total Debt | $1.80M |
| Free Cash Flow | $20.14M |
Source: Nexqual, July 25, 2026 at 03:57 UTC.
Financial Health Score (CFOR)
Nexqual rates Capforce Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 03:57 UTC.
| Growth | Critical — Revenue -39% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Solid — $79K cash vs $2M debt |
| Cash Flow | Strong — FCF $20M, 772% margin |
| Efficiency | Strong — ROE 122%, ROA 63.3% |
Ownership (CFOR)
| Insider Ownership | +85.50% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 12.38M |
| Float | 3.87M |
| Short % of Float | +1.79% |
Source: Nexqual, July 25, 2026 at 03:57 UTC.
Leadership (CFOR)
Capforce Inc. is led by Christian-Laurent Benoit Bonte (age 46), Chief Executive Officer, per Nexqual as of July 25, 2026 at 03:57 UTC.
| Chief Executive Officer | Christian-Laurent Benoit Bonte (age 46) |
|---|---|
| Chief Operating Officer | Mohd Azham bin Azudin (age 52) |
| Chief Technology Officer | Syed Johan Bin Syed Mohd (age 36) |
From Capforce Inc.'s Latest SEC 10-K Filing (filed 2026-05-26)
Key Strengths & Strategy (as disclosed to the SEC)
- This strategy leverages a combination of copyrights for our proprietary software code, user interface frameworks, and content; and trade secrets, including know-how, to safeguard our core algorithms, AI models, and confidential operational methodologies.
Partnerships
- In connection with the transactions contemplated by the March 2024 Purchase Agreement, the members of the Board of Directors, prior to the closing of such transactions, resigned, a new Board of Directors was appointed, of which Mr.
- With regard to public listing advisory services, CapForce must comply with any exchange-specific requirements.   Investment Advisory and Model-Enabled Advisory Regulation   The advanced computational model-enabled investment banking advisory platform to be offered by CapForce may be subject to investment advisory regulations in markets such as the U.S., Singapore, and Hong Kong.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AYTU | Aytu BioPharma, Inc. | USD 2.16 | ▲ 0% |
| PRPO | Precipio, Inc. | USD 23.68 | ▲ 0.85% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
| TENX | Tenax Therapeutics, Inc. | USD 14.53 | ▼ 1.76% |
| AIM | AIM ImmunoTech Inc. | USD 0.25 | ▼ 0.4% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 03:57 UTC. This page is informational and not investment advice.